期刊文献+

厄洛替尼-化疗交替在晚期非小细胞肺癌一线治疗中的效果

原文传递
导出
摘要 目的:探讨研究厄洛替尼-化疗交替在晚期非小细胞肺癌一线治疗中的效果。方法:随机选取2013年1月~2015年1月我院收治的晚期非小细胞肺癌患者40例,分为对照组20例和实验组20例,对照组的患者给予口服厄洛替尼治疗,实验组患者给予厄洛替尼-化疗支替治疗.观察两组患者的治疗效果。结果:实验组患者的完全缓解率、部分缓解率、稳定率以及疾病进展率率分别为25%、35%、35%、5%;对照组患者的完全缓解率、部分缓解率、稳定率以压疾病进展率分别为0%、20%、50%、30%,差异具有统计学意义。结论:厄洛替尼-化疗交替在晚期非小细胞肺癌一线治疗比单独使用厄洛替尼治疗的效果更好,并且毒性较低,具有良好的耐受性和安全性。
作者 陈志宾
出处 《医学与社会》 2015年第B05期207-207,共1页 Medicine and Society
  • 相关文献

参考文献5

二级参考文献21

  • 1Julia Neperud,Armeen Mahvash,Naveen Garg,Ravi Murthy,Janio Szklaruk.Can imaging patterns of neuroendocrine hepatic metastases predict response yttruim-90 radioembolotherapy?[J].World Journal of Radiology,2013,5(6):241-247. 被引量:3
  • 2Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National CancerInstitute of Canada Clinical Trials Group Study BR.21. J Clin Oncol, 2006, 24(24): 3831-3837.
  • 3Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancer from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Nail Acad Sci USA, 2004, 101 (36): 13306-13311.
  • 4Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Onco 1, 2004, 22 (16): 3238-3247.
  • 5Huang S, Armstrong EA, Benavente S, et al. Dual-agent molecular targetingof the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res, 2004, 64(15): 5355-5362.
  • 6Paz-ares L, Sanchez JM, Garcia-velasco A, et al. A prospective phase II trial Of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutation in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin oncol, 2006, 24(18s): 7020.
  • 7Normanno N, Bianco C. De Luca A, et al. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat cancer. 2003, 10(1): 1-21.
  • 8Salomon D S, Brandt R, Ciardiello F, et al. Epidermal of growth factor related peptides and their receptors in human malignancies. Crit Rev oncol Hematol, 1995, 19(3): 183-232.
  • 9Fontanini G, De Laurentiis M, Vignati S, et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IliA non-small-cell lung cancer: ampbiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res, 1998, 4(1): 241-249.
  • 10Shepherd FA, Rodrigues P.l, Ciuleanu T. et al. Edotirtib in previously treated non-small ceil lung cancer. N EnglJ Med, 2005, 353(2): 123-132.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部